FGP
NVAX icon

Freestone Grove Partners’s Novavax NVAX Stock Holding History

Freestone Grove Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Sell
26,223
-1,953
-7% -$17.5K ﹤0.01% 783
2026
Q1 		$229K Sell
28,176
-68,824
-71% -$624K ﹤0.01% 721
2025
Q4 		$652K Buy
+97,000
New +$731K ﹤0.01% 531
2025
Q2 		– Sell
-14,091
Closed -$90.3K – 802
2025
Q1 		$90.3K Sell
14,091
-34,590
-71% -$286K ﹤0.01% 562
2024
Q4 		$391K Buy
+48,681
New +$469K ﹤0.01% 420

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Freestone Grove Partners's NVAX Position: Q2 2026 in Review

Freestone Grove Partners reduced its Novavax (NVAX) stake by 6.9% in Q2 2026, selling an estimated $17.5K and leaving 26,223 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #783.

Freestone Grove Partners first reported a position in NVAX in Q4 2024 and has held it in 5 quarters since. The position peaked at $652K in Q4 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Freestone Grove Partners held 26,223 shares of Novavax worth $247K as of Q2 2026.
  • Freestone Grove Partners sold 1,953 Novavax shares in Q2 2026, an estimated $17.5K.
  • Novavax made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #783 holding.
  • Freestone Grove Partners first reported a position in Novavax in Q4 2024 and has held it in 5 quarters since.
  • Freestone Grove Partners's Novavax position peaked at $652K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.